BMS Highlighted Long-Term Follow-Up Results from Two P-III Studies of Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Shots:
- The 2 P-III studies i.e., 56wk. analysis of (VALOR-HCM) LTE study & 120wk. analysis of the (EXPLORER) cohort of the (MAVA-LTE) study evaluating Camzyos. In the (VALOR-HCM LTE) study, improvements across study EPs in Camzyos over 56wks. & those transitioned to the PBO group over 40wks.
- 8.9% vs 19.2% decided to proceed with SRT or were SRT-eligible, sustained reduction in peak resting LVOT gradient (-34.0 vs -33.2mmHg), NYHA class improvement of ≥1 class (93% vs 73%), avg. scores of symptom frequency, symptom burden & physical limitation continued to improve
- Reduction across biomarkers of cardiac wall stress & myocardial injury incl. reduction in NT-proBNP & cardiac troponin I. In the (EXPLORER-LTE) study, 75.9% improved by ≥1 NYHA class from baseline at the start of the LTE study to 120wk., improvements from baseline in echocardiographic parameters, mean LVEF remained within the normal range at all study visits & no new safety signals were seen in both studies
Ref: Businesswire | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
